XML 25 R5.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Statements of Cash Flows - USD ($)
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Cash flows from operating activities:    
Net income (loss) $ (1,402,433) $ 144,661
Discontinued operations 0 495,410
Net income (loss) from continuing operations (1,402,433) (350,749)
Adjustments to reconcile net income (loss) from continuing operations to net cash provided by operating activities:    
Depreciation and amortization expense 1,653,746 1,227,607
Share-based compensation 159,901 162,960
Increase (decrease) in non-cash contingent consideration 370,464 (280,020)
Decrease (increase) in cash surrender value of life insurance policies over premiums paid 222,209 (76,300)
Decrease (increase) in noncash interest expense 2,183 13,833
Net changes in assets and liabilities affecting operating activities:    
Accounts receivable (7,758,089) (171,584)
Inventories 2,271,484 1,868,350
Other current assets and other assets 239,862 507,102
Accounts payable and other current liabilities 4,461,389 (1,311,123)
Other long-term liabilities (371,214) (299,937)
Net cash provided by (used in) operating activities from continuing operations (150,498) 1,290,139
Discontinued operations 0 495,410
Net cash provided by (used in) operating activities (150,498) 1,785,549
Cash flows from investing activities:    
Additions to property and equipment (26,986) (19,458)
Note receivable investment funding 0 (200,000)
Cash paid for acquisitions (13,500,000) 0
Additions to intangible assets (14,912) (98,883)
Net cash used in investing activities (13,541,898) (318,341)
Cash flows from financing activities:    
Borrowings on line of credit 20,000,000 15,000,000
Repayments on line of credit (15,000,000) (15,000,000)
Cash payment of contingent consideration (501,505) (995,277)
Repurchase of common shares (580,130) (302,802)
Net cash provided by (used in) financing activities 3,918,365 (1,298,079)
Net increase (decrease) in cash and cash equivalents (9,774,031) 169,129
Cash and cash equivalents at beginning of period 27,040,816 24,753,796
Cash and cash equivalents at end of period $ 17,266,785 $ 24,922,925